The company is led by Kevin G. Connors, the General Partner at Newton, Mass.-based Spray Venture Partners, which he founded in 1996. He has co-founded seven healthcare technology companies and has had interim CEO roles at nine. Prior to founding Spray, he was the founding Chief Executive Officer and Director at Vesica Medical. Earlier, he led medical device investment activity at DSV Partners in Newport Beach, Calif. He has also served on the boards of the New England Venture Capital Association and MassMEDIC.
Named in the current SEC filing along with Connors were company directors J. Daniel Cole, of Spray Venture Partners; William H. Gruber, President of Cambridge Innovation research, former CIO of Risk Management Foundation of the Harvard Medical Institutions; and William Pintauro.
Solace Therapeutics develops non-surgical office-based treatments for common bladder disorders such as stress urinary incontinence, overactive bladder, male voiding dysfunction, and lower urinary tract symptoms. Incorporated in 2002, the company is based in Framingham, Mass.
